NeuroSense’s innovative combination therapy, presents a groundbreaking approach addressing Alzheimer’s disease (AD). Unlike existing treatments that primarily target amyloids, NeuroSense is utilizing a multi-targeted strategy, including reducing inflammation, oxidative stress, and Aβ aggregation.

The Company is currently enrolling patients in RoAD, a Phase 2 clinical study (NCT06185543), at Rambam Health Care Campus. RoAD is a randomized, double-blind, placebo-controlled trial, designed to evaluate the safety, efficacy, and biological activity of PrimeC – the initial formulation of what will eventually evolve into CogniC. This cutting-edge trial leverages advanced biomarker analysis and clinical assessments, positioning CogniC as a novel candidate to transform AD therapy.

Participants receive PrimeC for 12 months and undergo fluid and digital biomarker assessments, clinical evaluations, and safety monitoring.
The results of this trial will pave the way for the development and optimization of CogniC, an innovative next-generation formulation, designed to potentially transform the treatment landscape for AD. By integrating traditional biomarkers from both CSF and blood with cutting-edge analytical approaches and digital biomarkers, this study aims to provide a holistic view of CogniC’s therapeutic promise, offering both potential efficacy and a strong safety profile.